Burst CME™: Biomarkers in Diffuse Large B-cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

This podcast includes a discussion with 2 experts on biomarkers that may inform treatment selection for patients with DLBCL. Optimal selection of treatment along the therapeutic continuum depends on careful consideration of patient and disease factors. This activity is supported by an educational grant from Pfizer Inc.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions on How to Receive Credit

1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 3903
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
5. You may immediately download your certificate.

Today’s faculty are:

Matt Lunning, DO, FACP
Associate Professor
Medical Director, Cellular Therapy
Associate Vice-Chair Research, Department of Medicine
Assistant Vice Chancellor for Clinical Research
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, NE

Grzegorz S. Nowakowski, MD, FASCO
Professor of Medicine and Oncology
Chair, Lymphoid Malignancy Group
Enterprise Deputy Director, Clinical Research
Mayo Clinic Comprehensive Cancer Center
Vice-Chair Division of Hematology
Rochester, MN

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Release Date

November 26, 2024

Expiration Date

November 26, 2025